SCHEMBL6723607

SCHEMBL6723607

Cc1ncccc1-c1noc(C(F)F)c1-c1ccc(S(N)(=O)=O)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.41
PTGS1 P23219 4/20 0.41
BRD4 O60885 1/20 0.38
BRD2 P25440 1/20 0.38
BRD3 Q15059 1/20 0.38
ALOX5AP P20292 7/20 0.38
FEN1 P39748 7/20 0.38
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37
CA4 P22748 1/20 0.37
NR3C1 P04150 1/20 0.35
PGR P06401 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6725484 0.91 PTGS2 (0.40) PTGS2PTGS1ALOX5APFEN1NR3C1
SCHEMBL6732888 0.88 CA1 (0.36) PTGS2PTGS1BRD4ALOX5APFEN1
SCHEMBL6730202 0.87 BRD4 (0.49) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6733324 0.87 ALOX5AP (0.35) PTGS2BRD4BRD2BRD3ALOX5AP
SCHEMBL6730206 0.84 PTGS2 (0.47) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6721861 0.84 PTGS2 (0.43) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6721596 0.84 PTGS2 (0.47) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6722029 0.83 PTGS2 (0.44) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6728872 0.83 CA2 (0.47) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6721775 0.83 PTGS2 (0.47) PTGS2PTGS1BRD4BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885BRD4 384/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885BRD4 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.